Ireland
--:--IST
Latest
Clinical Trials in Italy / NCT07628205
Enrolling by invitation Phase 2

Preoperative Botulinum Toxin A to Facilitate Midline Closure in Large Chronic Ventral Hernias

NCT07628205 · tracked via the Priya Life Science Italy tracker
Phase
Phase 2
Started
2026-02-17
Last updated
2026-06-04

Condition(s) studied

Hernia

Investigational drug(s) / intervention(s)

Posterior Component Separation (PCS) with TARRives-Stoppa

Posterior Component Separation (PCS) with TAR: Posterior Component Separation (PCS) with Transversus Abdominis Release (TAR) is an intraoperative surgical technique performed by the surgeon when a standard retromuscular repair, such as the Rives-Stoppa technique, does not allow for tension-free midline closure. In such cases, additional myofascial release is required, and PCS with TAR is subsequently performed to achieve adequate medial advancement of the abdominal wall components and enable secure, tension-free closure of the midline defect.

Rives-Stoppa: Rives-Stoppa repair is a retromuscular abdominal wall reconstruction technique used when primary fascial closure can be achieved without the need for additional myofascial release. It represents a less invasive approach compared to component separation techniques, such as Posterior Component Separation with Transversus Abdominis Release (PCS with TAR), and is performed in cases where tension-free midline closure is feasible using a standard retromuscular plane dissection.

Study summary

In patients with large hernias, chronic retraction of the lateral abdominal wall muscles, and visceral contents that are irreducible within the hernia sac, closure of the midline can be difficult or even impossible. Component separation techniques (CST), in combination with transversus abdominis release (TAR), increase the flexibility of the abdominal wall and facilitate fascial medialization. However, these techniques alter the anatomy of the abdominal wall and are associated with higher risks of wound complications, abdominal wall disruption, and abdominal compartment syndrome (ACS).

Recently, the preoperative injection of Botulinum Toxin A (BTA) has been proposed as an effective form of chemical component separation of the muscles, or more precisely, chemical relaxation. It has been hypothesized that preoperative chemical paralysis of the lateral abdominal wall muscles through BTA increases abdominal wall compliance and facilitates fascial medialization, thereby reducing the need to resort to CST.

However, the current literature still lacks studies evaluating the impact of BTA on predictive scores for myofascial release and the correlation with intraoperative strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the trial * Compliance to follow-up * Male and female * Written informed consent to preoperative BTA injection and/or surgery * Age 18 years old * Primary ventral hernia * Incisional ventral hernia * RDR \< 2 * Defect width 10 cm * Loss of domain (LoD) 20% Exclusion Criteria: * Medical or psychiatric conditions that compromises the patient's ability to give informed * consent or comply with the study protocol * Personal reasons * Age \< 18 years old * RDR ≥ 2 * Defect width \< 10 cm * LoD \< 20% * Pregnancy and breastfeeding * Allergy/Intolerance to BTA * Neuromuscular disorders and diseases * Refuse to give informed consent to preoperative BTA injection and/or surgery

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Asst Ovest Milanese Legnano Milano

More Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano trials in Italy

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07628205 on ClinicalTrials.gov ↗ ← All trials in Italy